Thrombocytopenia in Systemic Lupus Erythematosus

@article{Jung2016ThrombocytopeniaIS,
  title={Thrombocytopenia in Systemic Lupus Erythematosus},
  author={Jin-Hee Jung and Moon-Seung Soh and Young-Hwan Ahn and Yoo Jin Um and Ju-Yang Jung and Chang Hee Suh and Hyoun-Ah Kim},
  journal={Medicine},
  year={2016},
  volume={95}
}
AbstractThe aim of the study was to examine the clinical characteristics and prognosis according to severity of thrombocytopenia and response to treatment for thrombocytopenia in patients with systemic lupus erythematosus (SLE).We retrospectively evaluated 230 SLE patients with thrombocytopenia, and reviewed their clinical data and laboratory findings. Thrombocytopenia was defined as platelet counts under 100,000/mm3, and patients were divided into 3 thrombocytopenia groups according to… 
Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
TLDR
Thrombocy topenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity and patients with SLE-related thromb cytotenia has a decreased long-term survival rate.
Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases
TLDR
Among various CTDs, severe thrombocytopenia often occurs in patients with SLE or pSS, and early response to the treatments, but not the background disease, is an important predictor of long-term prognosis.
Mean Platelet Volume on Systemic Lupus Erythematosus Patients with and without Thrombocytopenia in Dr Hasan Sadikin Hospital Bandung: A Descriptive Study
TLDR
Group with normal MPV value and normal platelet count has the largest proportion, while the group with thrombocytopenia in lupus and high MPVvalue has the lowest proportion.
Lupus thrombocytopenia: pathogenesis and therapeutic implications
TLDR
There is no consensus on the treatment of refractory lupus thrombocytopenia due to the absence of controlled randomized trials, but there are no evidence-based guidelines to facilitate selection of one drug over another.
Prevalence and influential factors of thrombocytopaenia in systemic lupus erythematosus patients: a retrospective analysis of 3140 cases in a Chinese population
TLDR
Thrombocytopaenia has a high prevalence in SLE patients and is related to some baseline, clinical and laboratory characteristics, affecting multiple organs and systems.
Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series
TLDR
This case series suggests that TPO mimetics are safe and moderately effective in patients with ITP in the setting of SLE or APS and do not contribute to increased disease activity.
Associated clinical factors for serious infections in patients with systemic lupus erythematosus
TLDR
Serositis, hematologic involvement, and use of higher than the low dose of GCs were associated with serious infections in patients with SLE, a nested case-control study using electronic medical records data.
Study of Iron profile Level in Lupus Nephritis
TLDR
Ferritin levels correlate with disease activity in patients with SLE and developing of lupus nephritis, and hyperferritinemia is a useful marker in assessment of disease activity and severity of Albuminuria in SLE patients complicated by LN.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus
TLDR
The results, concerning North-African SLE patients, confirm the findings of previous studies which suggest that thrombocytopenia correlates with more severe disease and has a negative impact on the survival of lupus patients.
Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor.
TLDR
Thrombocytopenia early in the course of SLE is indicative of more severe and active disease, and is also an independent predictor of mortality, albeit of a lesser magnitude than that predicted by poverty.
Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.
TLDR
Longterm remission was obtained in the majority of patients, mainly as a result of splenectomy or combined treatment with prednisone and either danazol or hydroxychloroquine.
Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases.
TLDR
Danazol therapy seems to be a useful and well-tolerated treatment for refractory immune thrombocytopenia associated with different rheumatic diseases.
Haematological manifestations of lupus
TLDR
Through a review, it is concluded glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely, and rituximab is promising in refractory and non-responding AIHA.
The significance of thrombocytopenia in systemic lupus erythematosus.
TLDR
Thrombocytopenia clearly is not a prognostic indicator in systemic lupus erythematosus, and 2 distinct subgroups are revealed; serious bleeding was rare in both subgroups.
Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus
TLDR
Two distinct subsets of SLE patients with thrombocytopenia have been identified, one in which the throm bocy topenia is an active disease associated with SLE, and the other in which throm B-cells with no CD19+ cells are an isolated finding that occurs independently of Sle activity.
Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus.
TLDR
Monthly intravenous cyclophosphamide therapy is potentially useful for the management of autoimmune thrombocytopenia in patients with systemic lupus erythematosus who are refractory to or dependent on unacceptably high doses of corticosteroids, or are experiencing side effects of conventional medical or surgical treatment.
Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
TLDR
The presence of nephritis and seizures each increased the risk of death in patients with SLE approximately 2-fold, and the presence of leukopenia was protective.
Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems.
TLDR
The data demonstrate that both haemolytic anaemia and thrombocytopenia are associated with ACL but not anti-dsDNA antibodies, and that renal, central nervous system involvement and general symptoms are more frequently present in patients with severe haematological crisis.
...
...